Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Bristol Myers Squibb (BMYMP) Assets (2016 - 2025)

Bristol Myers Squibb (BMYMP) has disclosed Assets for 17 consecutive years, with $90.0 billion as the latest value for Q4 2025.

  • Quarterly Assets fell 2.77% to $90.0 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $90.0 billion through Dec 2025, down 2.77% year-over-year, with the annual reading at $90.0 billion for FY2025, 2.77% down from the prior year.
  • Assets for Q4 2025 was $90.0 billion at Bristol Myers Squibb, down from $96.9 billion in the prior quarter.
  • The five-year high for Assets was $112.4 billion in Q1 2021, with the low at $90.0 billion in Q4 2025.
  • Average Assets over 5 years is $98.5 billion, with a median of $96.0 billion recorded in 2022.
  • The sharpest move saw Assets decreased 13.49% in 2021, then increased 5.04% in 2024.
  • Over 5 years, Assets stood at $109.3 billion in 2021, then dropped by 11.43% to $96.8 billion in 2022, then dropped by 1.72% to $95.2 billion in 2023, then dropped by 2.69% to $92.6 billion in 2024, then fell by 2.77% to $90.0 billion in 2025.
  • According to Business Quant data, Assets over the past three periods came in at $90.0 billion, $96.9 billion, and $94.7 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.